Literature DB >> 20603440

International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment.

S Dawood1, S D Merajver2, P Viens3, P B Vermeulen4, S M Swain5, T A Buchholz6, L Y Dirix7, P H Levine8, A Lucci9, S Krishnamurthy10, F M Robertson11, W A Woodward6, W T Yang12, N T Ueno13, M Cristofanilli14.   

Abstract

BACKGROUND: Inflammatory breast cancer (IBC) represents the most aggressive presentation of breast cancer. Women diagnosed with IBC typically have a poorer prognosis compared with those diagnosed with non-IBC tumors. Recommendations and guidelines published to date on the diagnosis, management, and follow-up of women with breast cancer have focused primarily on non-IBC tumors. Establishing a minimum standard for clinical diagnosis and treatment of IBC is needed.
METHODS: Recognizing IBC to be a distinct entity, a group of international experts met in December 2008 at the First International Conference on Inflammatory Breast Cancer to develop guidelines for the management of IBC.
RESULTS: The panel of leading IBC experts formed a consensus on the minimum requirements to accurately diagnose IBC, supported by pathological confirmation. In addition, the panel emphasized a multimodality approach of systemic chemotherapy, surgery, and radiation therapy.
CONCLUSIONS: The goal of these guidelines, based on an expert consensus after careful review of published data, is to help the clinical diagnosis of this rare disease and to standardize management of IBC among treating physicians in both the academic and community settings.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20603440      PMCID: PMC3105293          DOI: 10.1093/annonc/mdq345

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  54 in total

1.  The impact of immediate breast reconstruction on the technical delivery of postmastectomy radiotherapy.

Authors:  Sabin B Motwani; Eric A Strom; Naomi R Schechter; Charles E Butler; Gordon K Lee; Howard N Langstein; Steven J Kronowitz; Funda Meric-Bernstam; Nuhad K Ibrahim; Thomas A Buchholz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-06-09       Impact factor: 7.038

2.  Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute.

Authors:  Kenneth W Hance; William F Anderson; Susan S Devesa; Heather A Young; Paul H Levine
Journal:  J Natl Cancer Inst       Date:  2005-07-06       Impact factor: 13.506

Review 3.  Evolving role of positron emission tomography in breast cancer imaging.

Authors:  William B Eubank; David A Mankoff
Journal:  Semin Nucl Med       Date:  2005-04       Impact factor: 4.446

4.  Rho GTPases are over-expressed in human tumors.

Authors:  G Fritz; I Just; B Kaina
Journal:  Int J Cancer       Date:  1999-05-31       Impact factor: 7.396

5.  Long-term results of combined-modality therapy for inflammatory breast carcinoma.

Authors:  Editta Baldini; Giovanni Gardin; Giuseppe Evagelista; Tiziana Prochilo; Paola Collecchi; Rita Lionetto
Journal:  Clin Breast Cancer       Date:  2004-12       Impact factor: 3.225

6.  Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer.

Authors:  N Cabioglu; Y Gong; R Islam; K R Broglio; N Sneige; A Sahin; A M Gonzalez-Angulo; P Morandi; C Bucana; G N Hortobagyi; M Cristofanilli
Journal:  Ann Oncol       Date:  2007-03-09       Impact factor: 32.976

7.  p53 expression as a prognostic marker in inflammatory breast cancer.

Authors:  Ana M Gonzalez-Angulo; Nour Sneige; Aman U Buzdar; Vicente Valero; Shu-Wan Kau; Kristine Broglio; Yuko Yamamura; Gabriel N Hortobagyi; Massimo Cristofanilli
Journal:  Clin Cancer Res       Date:  2004-09-15       Impact factor: 12.531

8.  [High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: long-term results].

Authors:  F Conti; S Carpano; D Sergi; L Di Lauro; A Amodio; P Vici; M I Abbate; F R Ferranti; G Viola; C Botti; P Foggi; I Sperduti; M Lopez
Journal:  Clin Ter       Date:  2007 Jul-Aug

9.  Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience.

Authors:  Massimo Cristofanilli; Ana Maria Gonzalez-Angulo; Aman U Buzdar; Shu-Wan Kau; Debbie K Frye; Gabriel N Hortobagyi
Journal:  Clin Breast Cancer       Date:  2004-02       Impact factor: 3.225

10.  Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data.

Authors:  Selin Carkaci; Homer A Macapinlac; Massimo Cristofanilli; Osama Mawlawi; Eric Rohren; Ana M Gonzalez Angulo; Shaheenah Dawood; Erika Resetkova; Huong T Le-Petross; Wei-Tse Yang
Journal:  J Nucl Med       Date:  2009-01-21       Impact factor: 10.057

View more
  150 in total

1.  High-density and very-low-density lipoprotein have opposing roles in regulating tumor-initiating cells and sensitivity to radiation in inflammatory breast cancer.

Authors:  Adam R Wolfe; Rachel L Atkinson; Jay P Reddy; Bisrat G Debeb; Richard Larson; Li Li; Hiroko Masuda; Takae Brewer; Bradley J Atkinson; Abeena Brewster; Naoto T Ueno; Wendy A Woodward
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-01       Impact factor: 7.038

Review 2.  Management of locally advanced breast cancer-perspectives and future directions.

Authors:  Konstantinos Tryfonidis; Elzbieta Senkus; Maria J Cardoso; Fatima Cardoso
Journal:  Nat Rev Clin Oncol       Date:  2015-02-10       Impact factor: 66.675

Review 3.  Inflammatory breast cancer: what we know and what we need to learn.

Authors:  Hideko Yamauchi; Wendy A Woodward; Vicente Valero; Ricardo H Alvarez; Anthony Lucci; Thomas A Buchholz; Takayuki Iwamoto; Savitri Krishnamurthy; Wei Yang; James M Reuben; Gabriel N Hortobágyi; Naoto T Ueno
Journal:  Oncologist       Date:  2012-05-14

4.  The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.

Authors:  H Arias-Pulido; A Cimino-Mathews; N Chaher; C Qualls; N Joste; C Colpaert; J D Marotti; M Foisey; E R Prossnitz; L A Emens; S Fiering
Journal:  Breast Cancer Res Treat       Date:  2018-06-01       Impact factor: 4.872

5.  Inflammatory breast cancer: the experience of Baylor University Medical Center at Dallas.

Authors:  Justin M Goldfarb; John E Pippen
Journal:  Proc (Bayl Univ Med Cent)       Date:  2011-04

6.  Lymph node status in inflammatory breast cancer.

Authors:  Julie S Wecsler; Welela Tereffe; Rose C Pedersen; Michelle R Sieffert; Wendy J Mack; Haiyan Cui; Christy A Russell; Ryan R Woods; Rebecca K Viscusi; Stephen F Sener; Julie E Lang
Journal:  Breast Cancer Res Treat       Date:  2015-04-07       Impact factor: 4.872

7.  Locoregional therapy of locally advanced breast cancer: a clinical practice guideline.

Authors:  M Brackstone; G G Fletcher; I S Dayes; Y Madarnas; S K SenGupta; S Verma
Journal:  Curr Oncol       Date:  2015-03       Impact factor: 3.677

8.  Genomic profiling in locally advanced and inflammatory breast cancer and its link to DCE-MRI and overall survival.

Authors:  Sharareh Siamakpour-Reihani; Kouros Owzar; Chen Jiang; Peter M Scarbrough; Oana I Craciunescu; Janet K Horton; Holly K Dressman; Kimberly L Blackwell; Mark W Dewhirst
Journal:  Int J Hyperthermia       Date:  2015-03-26       Impact factor: 3.914

9.  An unexpected diagnosis of breast malignancy.

Authors:  T Richardson; F Cottier
Journal:  Ann R Coll Surg Engl       Date:  2017-07       Impact factor: 1.891

10.  Dermoscopy of inflammatory breast cancer.

Authors:  María Gabriela Vallone; Virginia Mariana González; José Gabriel Casas; Margarita Larralde
Journal:  An Bras Dermatol       Date:  2018-03       Impact factor: 1.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.